AUTHOR INDEX

Beaune, P. H. 193
Borden, E. C. 213

Chahl, L. A. 275
Cragg, G. 425

D'Incalci, M. 57

Escher, E. 37

Franceschini, G. 167

Garattini, S. 57
George, C. F. 81
Ghezzi, P. 57
Guengerich, F. P. 193

Hathcock, J. N. 67
Herberg, J. T. 151

Iyengar, R. 151

Mitchelson, F. 357

Potter, E. K. 251

Reicks, M. 67
Rich, K. A. 151
Roberts, J. 111
Ross, D. 231

Sirtori, C. R. 167
Sladek, N. E. 301
Stearns, M. E. 25
Suffness, M. 425

Tumer, N. 111

Upward, J. W. 81

Waller, D. G. 81
Werner, J. 1

SUBJECT INDEX

Acetaminophen
  elimination and sulfur amino acids 74–76
  toxic effects mechanism 202
Acrolein 322
Adaptation in thermoregulation control 14–20
Adverse drug reactions
  β-adrenoceptor antagonists 84, 85
  interferons 214, 215
AF-DX116, muscarinic receptor antagonist 363
Age *see also* elderly
  drug action 111–42
  drug distribution 120
  drug excretion 124, 125
  drug metabolism 122–24, 205
  drug–plasma protein binding 121
  pharmacodynamics 126
  pharmacokinetics 119–26
Alcohol and drug reaction 135–37
Aldehyde dehydrogenases, inhibitors of NAD-linked 339–43
Aldosterone, angiotensin-dependent secretion 47
Amino acids, nutrition and sulfur 67, 68
Antiarrhythmic agents
  Class II 81–99
  digitalis-induced arrhythmias 95, 96
  post-infarct use 91–95
Anticancer agents
  metabolism in cancer 57–63
    in vitro 57, 58
    in vivo 59
  metabolism of plant-derived 425–54
Antidromic vasodilatation 275–92
  mediators 277–79
  nerves involved 276
  opioids 287
  patho-physiological role 291, 292
  studies 275–77
  tissue distribution 289, 290
Antimitotic drugs, microtubules thiol disulfides 25–34
Antitumor agents *see also* anticancer agents
  quinone-containing 237–39
    structures 238
Arrhythmias, catecholamine excess 86–88
Atherosclerosis
  fibrate effects 167–86
  plasma lipid abnormalities 167–69
Atrial fibrillation 88
Atrial flutter 88

Benzhexol, muscarinic receptor antagonism 361, 362
Bezafibrate
  lipid lowering 178, 179
  structure 169
Brain
  muscarinic agonist binding 387
  muscarinic receptors 384–90
    allosteric interactions 386, 387
Bretylium tosylate
  antiarrhythmic effects 97, 98
  mechanism of action 96, 97
  myocardial infarction 98
  Bruceantin 425, 426
  structure 426

Calcitonin gene-related peptide (CGRP) and primary afferent neurons 284, 285
Cancer
  anticancer drug metabolism 57–63
  interferon effects 216–21
Capsaicin
  primary sensor neurons 280–83
  and substance P in skin 283
Cardiovascular system
  muscarinic mechanisms 376–80
  muscarinic receptors 381
Catecholamines
  cardiac rhythm 85
  excess and arrhythmias 86
Clofibrate
  coronary heart disease prevention 182–85
  lipid lowering 175
  liver cell effects 171
  structure 169
Coronary heart disease prevention and fibrates 182–85
Cyclophosphamide
  acrolein β-elimination 336
  AUC levels 318, 319
  clearance 315
  cytotoxic action 322–24
  excretion half-life 315–18
  metabolism 306–14
    modulation 332–43
    scheme 311
  oxidation 332–36
  pharmacokinetics 314
  -specific selectivity 324
  structure 303
  therapeutic efficiency 334
  therapeutic indices 328
  transport forms 312
Cytochrome P-450
  depression in invasive disease 59–62
  substrates *in vitro* 196, 197

Dicyclamine, selective antagonism 361, 362
Diet and drugs
  absorption 127, 128, 131
  action 127–42
  distribution 130
  drug excretion 133
  drugs affecting 136
  metabolism 131, 132
  pharmacodynamics 123, 134
  pharmacokinetics 127–33
Doxorubicin, tumor levels 62, 63

Drug action
  age and diet effects 111–42
  genetic factors 115–17
  interaction and toxicity 111
Drug disposition
  environmental factors 118
  factors affecting 116
Drug interactions 127
  basis 201, 202

Elderly
  drug elimination 123
  drugs, increased response 127
  drug-induced nutritional deficiency 140–42
  physiological changes 119
Ellipticine 426–33
  mechanism of action 432
  metabolism 427–32
  structure 427

Fatty acids, β-oxidation 174
Fenofibrate
  apoprotein levels 176
  structure 169
Fever, thermoregulation 12–14
Fibrates
  and atherosclerosis 167–86
  atherosclerosis progression 181, 182
  coronary heart disease progression 181–85
  drug interactions 170–72
  experimental atherosclerosis 180
  lipid lowering 174–80
  pharmacokinetics 172
  pharmacology 170–72
  structures 169
  toxicology 173
Free-radical
  binding species 235
  DNA strand breaks 236
  induced toxicity 231
  production 232
    enzymology 232, 233
  protective mechanisms 240–43
  redox cycling 233

Gallamine
  Arunlakshane–Schild Plot 365
  muscarinic receptor antagonism 363–68
Gastrointestinal tract
  muscarinic agonists 372, 373
  muscarinic antagonists 373, 374
Glutathione
  detoxification reactions 231
  radicals reacting 241, 242
Glutathione *S*-transferases, human 197, 198

Half-life, age and diet effects 113, 114
Harringtonine 432–34
  structure 434
Heat loss 7
Heat production 6, 7
  and core temperature 14
Histamine role, species differences 285
Hybridomas, muscarinic effects 394
4-Hydroxycyclophosphamide/aldophosphamide 324
  AUC values 326
  bladder toxicity 338
  cell kill 327
  cell sensitivity 331
  cyclophosphamide-specific toxicity 324–29

Immune system, liver drug metabolism 61
Indicine *N*-oxide 434–40
  metabolism scheme 436, 437
  structure 435
Interferons
  clinical trials 214
  industrial production 213
  pharmaceutical studies 215, 216
  phase II studies 216
  side effects 214, 215
  tumor effects 216–23
4-Ipomeanol 440–42
  structure 441

Kaposi's sarcoma, interferon effects 219

Leukemia, interferon effects 221
Leukocytes, oxidative bursts 236, 237
Lymphoma, interferon effects 222, 223

Malabsorption, drugs inducing 137, 138
Malignant melanoma and interferons 216, 217
McN-A-343, muscarinic receptor agonist 370
Mercapturic acid synthesis 70–73
Metabolism, drugs
  age effects 122–24, 205
  anticancer agents 57–63
  enzymes 200
  immune system regulation 61
  in vitro studies 193–99
    cells 194
    enzymes 196–99
    human 193–205
    subcellular 194, 195, 197
  plant-derived anticancer agents 425–54
  variability in individuals 203–205
Metabolites, drug 199
Methionine
  drug conjugations 67
  metabolism and intake 68–70
Microtrabecular lattice, drugs and 33
Microtubules
  antimitotic drug action 25–34
  assembly and tubulin 34
Microtubule-associated proteins (MAP) 29, 30
  erythrocytes 31
  thiol role 30–32
Mitotic spindle, microtubules 26, 27

Neurogenic inflammation
  mediators 277–79
  patho-physiological role 291, 292
Neuropeptides, primary afferent neurons 283–85
Neuropeptide Y
  amino acid sequences 252
  cholinergic interactions 265–67
  distribution 252, 253
  effects, whole body 254–56
  endogenous 256–58
  half-life 258

storage sites 254
structure 251, 252
sympathetic neuroeffector junction 260–65
arterial pressure 263
dose–response 262
prejunctional 264, 265
vasoconstrictor effects 259, 260
Nitrogen mustards
covalent bonds 305
structure 303
Nutrition *see also* diet
hyperexcretion 139, 140
Nutritional deficiencies
drug-induced 137–39
elderly 140–42

Oxazaphosphorines
acrolein β-elimination 308
carboxyphosphamide 309
clinical uses 302
cytotoxic action 321
metabolism 301–45
plasma elimination half-life 315–18
-specific selectivity 329–32
structures 302
synthesis 304
Oxidative stress, protein-mixed disulfide formation 243

Pharmacodynamics, age effects 118–27
Pharmacogenetics
age and diet effects 115, 116
drug response 117
Pharmacokinetics, age and diet effects 112–15
Phosphoramide mustard cytotoxicity 321
Photoaffinity analogues, structure–activity
angiotensin and bradykinin 43, 44
Photoaffinity labeling 37–53
angiotensin 38, 39
structure–activity 41
bradykinin 38
structure–activity 42
inactivation studies 44–48
label synthesis 39, 40
receptor responses 47
Phyllanthoside 442, 443
structure 442
Pilocarpine, muscarinic receptor agonist 369, 370
Pirenzepine
muscarinic receptor antagonism 357–61
pA_2 values 403
Podophyllotoxin
metabolism 443–48
structure 443
Prenylamine 98

Receptor
denaturation 50
frozen equilibrium 51–53
isolation studies 48–50
Receptors β-adreno-antagonists 81
competitive 82
electrophysiological effects 86
membrane stabilizing 83, 84
pharmacokinetics 84
post-infarct antiarrhythmic effects 91–94
selectivity 82, 83
Receptors, angiotensin
photoaffinity labeling 38
Receptors, bradykinin, photoaffinity labeling 37, 38
Receptor, glucagon
elastase treatment 159
endoglycosidase treatment 161, 162
GTP effects 155
high molecular weight form 157
hormone binding 160
labeling 151, 152
molecular parameters 156
protease effects 158
scheme 162
species comparisons 163, 164
structure, rat liver 152–63
Receptor, muscarinic
activation–response coupling 400–402
brain 384–90
cardioselective antagonists 383
cardiovascular system 376–83
differentiation 357–408
gastrointestinal tract 372–76
pirenzepine effects 395
prejunctional 390–94
agonist studies 391
antagonist studies 392–94
second messengers 398, 399
selective agonists 369–72
selective antagonists 357–61
subtypes 402–408
working classification 408
Xenopus oocytes 397, 398
Receptors, substance P 288
Redox cycling 234
Renal cell carcinoma, interferon effects 217, 218

Second messenger, muscarinic receptor 398–400
Secoverine, muscarinic receptor antagonism 368, 369
Shivering threshold 18
Substance P
antidromic vasodilatation 280
immune system effects 290, 291
isolation 279, 280
membrane mechanisms 289
primary afferent neuron release 286
primary afferent transmitter 286
spinal cord 286
Sulfate ester synthesis 73–77
Sulfhydryls, organelle transport 28
Supraventricular tachycardias 89, 90
Sweating threshold 18
Switching neuron 19

Tachykinins, amino acid sequences 278
Taxol structure 448, 449
Temperature regulation *see* thermoregulation
Thermoregulation
basic concept 2, 3
closed loop treatment 8–20
cold defence 11, 12
control loop 1, 2
adaptation 14–20
subsystems 3, 4
open loop treatment 3–8
sensors 4–6
steady state regulation 9
warm defence 10, 11

Thiols
  ATPase regulation 28
  depletion and cytomatrix 32, 33
Tienelic acid toxicity 203
Transsulfuration pathway 69
Triple response 275

Ventricular arrhythmias 90, 91
Vinblastine
  assay methods 450
  metabolism 449–54
  metabolites 452, 453
  structure 450
Vincristine
  metabolism 449–54
  structure 450
Vitamins
  antagonists 135
  and drug action 134, 135

Wolff–Parkinson–White syndrome 89

Reproduced with the permission of Pergamon Press Inc., by University Microfilms Inc. Duplication or resale without permission is prohibited.